RT Journal Article
SR Electronic
T1 Chikungunya Seroprevalence among Patients Presenting with Febrile illnesses in selected health facilities in Mt. Elgon region, Kenya
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.04.26.24306414
DO 10.1101/2024.04.26.24306414
A1 Kageha, Sheila
A1 Ngoi, Joyce M.
A1 Kubo, Toru
A1 Morita, Kouichi
A1 Mwau, Matilu
YR 2024
UL http://medrxiv.org/content/early/2024/04/27/2024.04.26.24306414.abstract
AB Background Chikungunya is an emerging epidemic-prone vector-borne disease of considerable significance globally. Infection with chikungunya virus induces an acute illness characterized by fever and painful arthralgia, which can evolve to chronic arthritis and rheumatism especially in elderly patients. Whereas febrile illness and arthralgia are common clinical presentations amongst residents of Mt. Elgon, the role of chikungunya virus as a causative agent is undocumented. This study was carried out to determine the prevalence of IgA, IgM and IgG antibodies against Chikungunya Virus (CHIKV) antigens in patients presenting with acute febrile illnesses in Mt. Elgon region, Kenya.Methods This was a cross-sectional seroprevalence study on febrile patients visiting Endebes, Andersen and Kitale County Referal Hospitals. Sociodemographic data was collected whenever possible. Serum samples were collected and screened using Indirect ELISA for 1gG+IgM+IgA antibodies. Sera that tested positive by ELISA were subjected to standard plaque reduction neutralization assays (PRNT) performed on monolayer cultures of Vero E6 cells for confirmation.Results By ELISA, a total of 317/1359 (23.33%) sera were positive for CHIKV antibodies. Of the 317 positive sera, 305 (96.21%) were of sufficient quantity and were subjected to PRNT. Ultimately, 127 (9.3%) samples tested positive for CHIKV neutralising antibodies by PRNT.Conclusion These findings suggest active circulation of CHIKV in Mt. Elgon, even though it has previously been considered a non-endemic region for the virus. There is need to closely monitor and continuously put in place surveillance strategies to prevent probable potential outbreaks in the future.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for the study protocol was sought from Kenya Medical Research Institute Ethical Review Committee under Scientific Steering Committee No.1698. Parental/guardian consent was sought for participants under 17 years of age.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll the data is in the manuscript. However, any extra data, if required can be made available on request.